Navigation Links
Pfizer Appoints Mikael Dolsten President of Worldwide Research and Development
Date:5/26/2010

NEW YORK, May 26 /PRNewswire-FirstCall/ -- Today, Pfizer Inc. (NYSE: PFE) named Mikael Dolsten, M.D., PhD, President of Pfizer Worldwide Research and Development, as the Company completes its integration of these functions following the Wyeth acquisition.  Dr. Dolsten previously led Wyeth's Research and Development organization from May 2008, and after the close of the Wyeth acquisition was named President of Pfizer's BioTherapeutics Research & Development.  Prior to his appointment at Wyeth, Dr. Dolsten held key leadership roles in R&D at Boehringer Ingelheim and AstraZeneca.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO )

With this appointment, Dr. Dolsten will now lead all of research at Pfizer, as well as development of all compounds through Phase 2, or 'proof of concept.'  Late-stage clinical development will continue to be led by clinical teams throughout the Worldwide Biopharmaceutical Businesses, as announced in April 2009.

"Since closing the Wyeth acquisition we have rapidly advanced integration, completing the pipeline portfolio review, finalizing decisions regarding our R&D network very quickly after close, and steadily progressing the pipeline.  Rapid integration has been enhanced by strong  and steady collaboration between the two legacy R&D groups -- making the consolidation under one leader a natural and pro
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... PHILADELPHIA , 22. Mai 2013 /PRNewswire/ ... Sitz in Barcelona , ... aufzeigt, dass eine höhere Dosis von PROLASTIN©-C ... Patienten mit Alpha1-Antitrypsinmangel (AAT) auf ein Niveau ... normal bezeichneten Bereichs liegt. ATT-Mangel ist eine ...
(Date:5/22/2013)... TORONTO , May 22, 2013  Medifocus, ... John Mon , Chief Operating Officer, will present ... May 30, 2013 in New York City ... Company,s presentation is scheduled to begin at 4:00 p.m. EDT ... the webcast, go to:   http://wsw.com/webcast/marcum/mfs.v/   For ...
(Date:5/22/2013)... 2013 Cellular Biomedicine Group (OTCQB: CBMG) today announced ... total projected enrollment required for its Phase I trial to ... Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the ... has had no Severe Adverse Effect (SAE) reported. ... registered with NIH under number NCT01828762 (click here to ...
Breaking Medicine Technology:Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer 2Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer 3
... world-leading developer and marketer of innovative medical technologies for community ... $10,000 to the AAWC Global Volunteers program through the SAWC ... 25th Annual Symposium on Advanced Wound Care and Wound Healing ... 22, 2012. The Association for the Advancement ...
... Fla., April 23, 2012  SurgLine International, Inc. (SGLN.PK) ... Inc. ("SGLN") and SurgLine, Inc. ("SurgLine") stated that ... has formed SurgLine MDC Holdings, LLC. ("SMDC"), a ... subsidiary.  SMDC will be forming  joint-venture opportunities with ...
Cached Medicine Technology:ConvaTec Donates $10,000 To AAWC Global Volunteers Program Through SAWC Walk For Wellness 2ConvaTec Donates $10,000 To AAWC Global Volunteers Program Through SAWC Walk For Wellness 3SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies 2
(Date:5/22/2013)... Teams who focus on productivity, process, quality, 5S ... StepTracker whiteboard as a rallying point for project management ... the current status of our company-wide lean initiatives and ... listed down the side and the milestones are along ... are filled with yellow circles. Turning the magnets over ...
(Date:5/22/2013)... 21 May 2013, Paris, France: Results from ... 2013 today question whether bivalirudin is superior ... blockade, showing similar 30-day mortality in patients ... (NSTE-ACS) undergoing percutaneous coronary intervention (PCI)., European ... alone as an alternative to unfractionated heparin ...
(Date:5/22/2013)... PA (PRWEB) May 22, 2013 The ... announce its participation in the Greater Philadelphia Tour de Cure, ... recreational riders who are passionate about stopping the spread ... 25 million Americans. , The Tour de Cure will ... at 580 Meetinghouse Road in Ambler, 30 minutes outside of ...
(Date:5/22/2013)... 22, 2013 According to the latest “ ... ” article published recently at FinancesOnline.com the wailing and flailing ... Centers for Disease Control and Prevention 2012 report points ... are overweight, 35.7% are obese, and 6.3% are extremely obese. ... article. In particular, the article focuses on a sector that ...
(Date:5/22/2013)... 2013 Synthetic Turf International has ... Play & Recreation Contest, who collectively have helped ... youth, people with disabilities, active troops and military ... general public is encouraged to vote online now ... non-profit organization win the $50,000 synthetic turf installation ...
Breaking Medicine News(10 mins):Health News:Project Managers Organize Manufacturing Projects and Training with the New Steptracker Project Status Magnetic Whiteboards 2Health News:Registry questions superiority of bivalirudin over heparin 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 3Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 2Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 3Health News:Public Voting Opens for Finalists in Synthetic Turf International’s Better Play & Recreation Contest 2
... News) --,Americans, awareness of chronic obstructive pulmonary disease (COPD) is ... their doctor about symptoms, according to a new survey by ... of COPD -- the third-leading cause of death in the ... wheezing, excess sputum production and a feeling of not being ...
... Randy Dotinga HealthDay Reporter , THURSDAY, Dec. ... physical activity might encourage better shut-eye: People who met ... fatigue than those who didn,t. The research doesn,t ... it,s possible there may be another explanation for the ...
... A diametric shift in the levels of two ... enables accumulation of the destructive brain plaque found in ... that folds others into specific positions to unleash their ... aging, it unleashes the normally dormant BACE1, a protein ...
... discovered that over a million people worldwide diagnosed with TB ... which is usually left untreated because it is mistaken for ... published today in the Bulletin of the World Health ... of Toronto say because the X-ray features and symptoms are ...
... WASHINGTON, Dec. 1, 2011 The American Chemical Society,s (ACS,) ... conferences of the New Year, will be held March ... place at the San Diego Convention Center and at area ... that span science,s horizons from astronomy to zoology ― ...
... that epigallocatechin-3-gallate (EGCG)a flavonoid found in green teainhibits the ... findings available in the December issue of Hepatology ... the American Association for the Study of Liver Diseases, ... prevent HCV reinfection following liver transplantation. HCV ...
Cached Medicine News:Health News:Many Ignore Symptoms of Lung Disease, Study Finds 2Health News:More Exercise Could Make For Better Sleep: Study 2Health News:More Exercise Could Make For Better Sleep: Study 3Health News:Diametric shift in 2 protein levels spurs Alzheimer's plaque accumulation 2Health News:Mistaken identity: New report highlights the global impact of medical misdiagnosis 2Health News:Green tea flavonoid may prevent reinfection with hepatitis C virus following liver transplantation 2
... The new SureCut M3500 Radial Microtome has ... is marvelous, and a range of functions and ... users. Based on years of experience and ... innovative design the SureCut M3500 Microtome will be ...
Clock oil, 6 grams net...
Knife sharpening back for Standard Knife, C Profile...
Knife sharpening kit...
Medicine Products: